Clinical Trial Detail

NCT ID NCT03414684
Title Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Nivolumab

Carboplatin

Age Groups: adult senior

No variant requirements are available.